Despite extensive efforts committed to the last decade in metabolic engineering of the medication in both microbial and heterologous plant systems, creation of artemisinin itself was hardly ever achieved. We wish that this invention will eventually help control this prevalent disease, for the advantage of many millions of people around the globe, and in particular in the developing globe., the technology transfer arm of the University of Jerusalem, introduces an innovative way allowing artemisinin production in a heterologous plant program, such as tobacco. The method was developed by Professor Alexander Vainstein from the Robert H. Smith Faculty of Agriculture, Food and Environment at the Hebrew University, and sponsored by a fellowship of Mr. Isaac Kaye. It was published under the title Generation of the Powerful Anti-Malarial Drug Artemisinin in Tobacco in the latest issue of the prestigious publication Nature Biotechnology.Rather, it releases a listing of the medical data section of the NDA , and FDA regulations allow the drug manufacturer to draft the Overview. The process reflects an understanding by the FDA that security and efficacy information ought to be protected, so that competing producers can’t make use of those data to develop generic alternatives or competing medicines. Consumer groups have got brought lawsuits against the FDA under the Freedom of Information Act to acquire safety data; these experienced mixed results. Lawsuits aren’t an ideal vehicle for consumer researchers and groups to gain access to data, given that litigation is costly and cases can take years to go through the legal system.